When discoveries from academic labs are developed into a blockbuster drug, universities often rake in big dollars from licensing revenue. With the translation of its life sciences research into commercial applications in mind, Harvard aims to put more financial muscle behind its 4-year-old Accelerator Fund, Xconomy's Greg Huang reports.
Huang got the scoop on Harvard's plans to raise $20 million to $30 million for the fund from the two bigwigs behind the effort: tech transfer legend Isaac Kohlberg, who serves as the Ivy League school's tech development head and senior associate provost, and Curtis Keith, the scientific chief of the Accelerator Fund and a co-founder of drug developer CombinatoRx (now called Zalicus). Kohlberg says the 5-year goal of the program is to have up to two drugs stemming from Harvard research enter clinical trials and for a start-up advancing Harvard technology to be in talks with a potential buyer.
To read the full, original article click on this link: With biotech wins, Harvard targets $20M-$30M for Accelerator - FierceBiotech
Author:Ryan McBride
